Results

1–10 of 64 results for socioeconomic

Evaluating the Visual, Anatomic, and Treatment Effects of Switching from Higher-cost Anti-VEGF to Lower-cost Bevacizumab After Loss of Copay Assistance (Good Days) Funding in Neovascular Age-Related Macular Degeneration
Jesse J Jung, MD, FASRS
Updates from the Field
2026
Impact of Loss of Good Days Copay Assistance Program on Clinical and Anatomical Outcomes of Retinal Disease
Danny A. Mammo, MD
Updates from the Field
2026
Biosimilar Paradox: How Biosimilar Use Will Increase Patient and Healthcare Costs
Ravi Parikh, MD MPH
Annual Meeting Talks
2023
Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration
Sabin Dang, MD
Annual Meeting Talks
2023
Bevacizumab-First vs Real-World Cost Outcomes for Diabetic Macular Edema: 2-Year Cost Analysis Modeled on DRCR Protocol AC Results
Dilraj S Grewal, MD, FASRS
Annual Meeting Talks
2023
Inflation-Adjusted Trends in Medicare Reimbursement for Retina Practice Expenses
Philip I Niles, MD, MBA
Annual Meeting Talks
2023
Demographic and Socioeconomic Predictors of Visual Outcomes in Pediatric Uveitis: An IRIS Registry Study
Akshay S Thomas, MD, MS, FASRS
Annual Meeting Talks
2023
Expert Panel: Socioeconomics
Linda A. Lam, MD, MBA, FASRS
Ella H Leung, MD
Mohsin H. Ali, MD
Hasenin Al-khersan, MD
Miguel A. Busquets, MD, FACS
Annual Meeting Talks
2024
Expert Panel: Sustainability
Geoffrey G. Emerson, MD, PhD, FASRS
Jacob D. Grodsky, MD
David R Anderson, MD, PharmD
Scott M McClintic, MD
Annual Meeting Talks
2024
A Discussion on Physician Contract Negotiations
Alexis Warren, MD
Talia R Kaden, MD
Jonathan Jonisch, MD
Webinars and Journal Clubs
2025